Indeed, ROCK inhibitors and SERT inhibitors have already been clinically approved and utilized for the treatment of certain diseases: the former for the treatment of vasospasm and subarachnoid hemorrhage complications40, and the latter for the treatment of depression41. Here, SLC6A4 is linked to subarachnoid hemorrhage.